Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer

NCT04262856 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

151

Enrollment

INDUSTRY

Sponsor class

Conditions

Non Small Cell Lung Cancer
Nonsquamous Non Small Cell Lung Cancer
Squamous Non Small Cell Lung Cancer
Lung Cancer

Interventions

DRUG: Domvanalimab
DRUG: Etrumadenant
DRUG: Zimberelimab

Sponsor

Arcus Biosciences, Inc.

Collaborators

[object Object]